Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT1 | P54687 | 1/20 | 0.37 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.32 |
| ▸ | CDK9 | P50750 | 3/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14600756 | 0.83 | HPGD (0.39) | BCAT1CCNE2CCNE1CDK2LRRK2 | |
| SCHEMBL14600775 | 0.80 | BCAT1 (0.39) | BCAT1CCNE2CCNE1CDK2 | |
| SCHEMBL14600777 | 0.74 | GSK3B (0.53) | HPGD | |
| SCHEMBL14600755 | 0.73 | BCAT1 (0.41) | BCAT1CCNE2CCNE1CDK2CCNT1 | |
| SCHEMBL14600776 | 0.71 | ALDH1A1 (0.46) | — | |
| SCHEMBL14600753 | 0.69 | GSK3B (0.53) | HPGD | |
| SCHEMBL14600754 | 0.69 | HPGD (0.42) | CCNE2CCNE1CDK2LRRK2HRH4 | |
| SCHEMBL5557730 | 0.68 | PLA2G7 (0.35) | PLA2G7HRH4HPGD | |
| SCHEMBL4833072 | 0.67 | TNIK (0.41) | CDK2LRRK2HPGD | |
| SCHEMBL5047846 | 0.67 | MAPK1 (0.47) | BCAT1HRH4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697352-B1 | 4-AZOLE SUBSTITUTED IMIDAZOLE COMPOSITIONS USEFUL AS INHIBITORS OR C-MET RECEPTOR TYROSINE KINASE | VERTEX PHARMA (US) | 2012-06-27 | — | — | EP | disclosed |
| US-7169800-B2 | Imidazole compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169800-B2 | Imidazole compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169800-B2 | Imidazole compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1697352-A2 | 4-AZOLE SUBSTITUTED IMIDAZOLE COMPOSITIONS USEFUL AS INHIBITORS OR C-MET RECEPTOR TYROSINE KINASE | Vertex Pharmceuticals Incorporated (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050148574-A1 | Imidazole compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-07-07 | — | — | US | disclosed |
| WO-2005040345-A2 | 4-AZOLE SUBSTITUTED IMIDAZOLE COMPOSITIONS USEFUL AS INHIBITORS OR C-MET RECEPTOR TYROSINE KINASE | VERTEX PHARMCEUTICALS INCORPORATED (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148574-A1 | Imidazole compositions useful as inhibitors of protein kinases | MAP3K20, PRKDC, MAP3K1 | BCAT1 844/4885PLA2G7 1849/4885CCNE2 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.